This case underscores the potential of Iruplinalkib, which is currently not available outside of China, to induce rapid and profound tumor regression in <i>ALK</i>-positive NSCLC, particularly in adolescent patients with aggressive clinical presentations. This evidence concerns the gene ALK and neoplasm.